Citizens maintains Market Outperform on Sagimet Biosciences with $27 price target

Citizens maintained its Market Outperform rating on Sagimet Biosciences, setting a price target of $27.00. This target implies a potential upside of 173.3% from the stock's closing price of $9.88 on September 30.